Form 4: PTGX Director Sells 4,000 Shares Under 10b5-1 Plan

Protagonist Therapeutics Director William D. Waddill sold 4,000 shares of common stock at $64.25 per share on September 22, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• William D. Waddill, a Director of Protagonist Therapeutics, Inc. (PTGX), reported the sale of 4,000 shares of common stock.
• The transaction occurred on September 22, 2025, at a price of $64.25 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Waddill on November 10, 2023.
• Following this transaction, Mr. Waddill directly beneficially owns 5,130 shares of Protagonist Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while reducing insider ownership, was conducted under a pre-arranged 10b5-1 plan, which mitigates the negative sentiment typically associated with unplanned insider selling. It is a neutral to slightly negative event.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction for personal financial management rather than an immediate reaction to company performance or outlook.

Negatives

• Insider selling, even if pre-arranged, can sometimes be perceived negatively by the market as it reduces insider ownership and could be interpreted as a lack of confidence, although this is mitigated by the 10b5-1 plan.

Risks

• Potential for negative market perception due to insider selling, which could lead to short-term stock price volatility, despite the transaction being pre-planned under a 10b5-1 plan.

Future Outlook

This filing reports a past transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged trading plan, which is a common practice among corporate executives and directors for personal financial planning. It does not inherently reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• This filing details a standard insider transaction (Form 4) executed under a Rule 10b5-1 plan, a common mechanism for corporate insiders to sell shares while avoiding accusations of trading on material non-public information. There are no specific comparable companies, projects, or results mentioned in the filing to assess against industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the reduction in director ownership with slight concern, though the 10b5-1 plan context typically lessens negative interpretations.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Recommendation

The filing reports a routine insider sale by a director under a pre-arranged 10b5-1 plan. While insider selling can sometimes be a negative signal, the pre-planned nature of this transaction suggests it is for personal financial management rather than a reflection of a negative outlook on the company's future. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, warranting a 'hold' position based solely on this filing.

Keywords

Protagonist Therapeutics, PTGX, insider trading, Form 4, stock sale, director, 10b5-1 plan, beneficial ownership